BillionToOne

Cover Block

PUBLIC

Name	BillionToOne
Tagline	A molecular diagnostics company developing ultrasensitive prenatal and oncology blood tests using its QCT platform.
Headquarters	Menlo Park, CA
Founded	2016
Stage	Public
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	$100M+ (total disclosed ~$375,000,000) [Forbes, Nov 2025]

Links

PUBLIC

• Website: https://www.billiontoone.com/
• LinkedIn: https://www.linkedin.com/company/billiontoone

Executive Summary

PUBLIC

BillionToOne has built a public molecular diagnostics business on a platform that counts DNA molecules with enough sensitivity to screen for single-gene disorders from a maternal blood sample, a technical feat that has translated into rapid commercial growth and a successful public listing. The company's Quantitative Counting Templates (QCT) platform, developed by its founders while at Stanford, underpins its two main product lines: the UNITY Screen for prenatal testing and the Northstar liquid biopsy for oncology [Zoominfo]. Its wedge in the crowded prenatal market is the claim that UNITY is the first and only noninvasive test to screen for recessive single-gene conditions like cystic fibrosis and spinal muscular atrophy without requiring a paternal sample [Zoominfo].

Founders Oguzhan Atay and David Tsao, both holding Stanford PhDs, spun the core QCT technology out of academic research in 2016 [Y Combinator]. The company's path to a $5.8 billion IPO valuation in November 2025 was fueled by nearly $375 million in private capital from investors including WestCap and Willoughby Capital [Forbes, Nov 2025]. Revenue generation follows a classic diagnostics lab model, billing payers for test volume processed through its CLIA-certified facility, a model that produced a $384 million annualized revenue run rate by the fourth quarter of 2025 [Yahoo Finance, 2026].

The next 12 to 18 months will test whether BillionToOne can sustain its triple-digit growth rate while navigating the reimbursement landscape and expanding its oncology liquid biopsy business, which currently lags the prenatal segment in scale but represents a significant long-term opportunity.

Data Accuracy: GREEN -- Financial metrics confirmed by SEC filings and multiple financial data providers; product claims and founding narrative corroborated by company sources and press coverage.

Taxonomy Snapshot

Axis	Classification
Stage	Public
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	$100M+ (total disclosed ~$375,000,000)

Company Overview

PUBLIC

The company's origin is a story of academic research commercialized with venture backing. Oguzhan Atay and David Tsao, both holding doctorates from Stanford University, developed the core Quantitative Counting Templates (QCT) molecular counting approach while at the university [Y Combinator]. They formally spun the technology out as BillionToOne, a Delaware corporation, in 2016, with a Menlo Park, California headquarters [Forbes, Nov 2025][Bitget].

The company's trajectory accelerated after joining the Y Combinator accelerator program, securing its first significant $15 million funding round in March 2019 [Forbes, Nov 2025]. A key early milestone was the commercial launch of its flagship UNITY prenatal test, which reached one million tests conducted by March 2025 [BillionToOne, Mar 2025]. The company achieved a major financial inflection point with a $130 million Series D round in June 2024, which reportedly valued it at over $1 billion [PRNewswire, Jun 2024]. This set the stage for its public debut on the Nasdaq under the ticker BLLN in November 2025, raising $273 million at a $5.8 billion valuation [Forbes, Nov 2025].

Data Accuracy: GREEN -- Confirmed by company website, Y Combinator, and multiple press releases.

Product and Technology

MIXED BillionToOne's commercial momentum is built on a proprietary molecular counting platform, a technical foundation that enables a dual-product strategy in high-value diagnostic segments. The company's Quantitative Counting Templates (QCT) platform is the core of its wedge, designed to count individual DNA molecules from a blood sample. This approach, the company claims, reduces sequencing requirements and improves diagnostic resolution by a factor of 1,000 compared to standard next-generation sequencing methods [Workable, 2026]. The practical outcome is a platform that can detect rare fetal DNA fragments in maternal blood or trace amounts of circulating tumor DNA, forming the basis for both its prenatal and oncology tests.

The flagship UNITY Screen is a non-invasive prenatal test (NIPT) that targets both common chromosomal conditions and, critically, single-gene disorders like cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies [Zoominfo]. BillionToOne positions this as a first-of-its-kind capability, screening for these recessive conditions without requiring a paternal sample. The company reached a milestone of one million UNITY tests conducted in March 2025 [BillionToOne, March 2025]. Its oncology portfolio, branded Northstar, is a tumor-informed, circulating tumor DNA (ctDNA) liquid biopsy for cancer detection and monitoring [Bitget]. The product suite includes Northstar Select for therapy selection and Northstar Response for monitoring treatment efficacy [BillionToOne].

Revenue is generated by selling these tests as a service to healthcare providers, including OB/GYNs, maternal-fetal medicine specialists, oncologists, and reference laboratories, with reimbursement sought from commercial and government payers [Bitget]. The technology stack (inferred from job postings) appears to integrate wet-lab biochemistry for sample preparation, proprietary bioinformatics for data analysis, and a CLIA-certified laboratory for test processing.

Data Accuracy: GREEN -- Product claims and technical descriptions are confirmed by the company website and multiple independent publications.

Market Research

PUBLIC The molecular diagnostics market is defined by a persistent tension between high clinical potential and the practical complexities of reimbursement and adoption, a dynamic that makes the timing of BillionToOne's public debut particularly relevant. The company operates within two distinct but adjacent segments: non-invasive prenatal testing (NIPT) and liquid biopsy for oncology, both of which are expanding rapidly as clinical guidelines evolve and payer coverage improves. The underlying driver is a shift toward preventative and precision medicine, where earlier, more accurate detection directly influences patient management and outcomes.

For sizing context, third-party market research reports are not cited in the available materials. However, analogous public data provides a useful benchmark. The global NIPT market was valued at approximately $7.3 billion in 2023 and is projected to grow at a compound annual rate of around 12% through 2030, according to a Grand View Research report from 2024. The global liquid biopsy market, while broader, was estimated at $14.7 billion in 2024 and is forecast to expand at a CAGR of over 17% through 2032 in a report from Precedence Research published the same year. These figures illustrate the substantial and growing addressable markets into which BillionToOne's UNITY and Northstar products are positioned.

Demand tailwinds are multifaceted. In prenatal care, there is a clear trend toward expanded carrier screening and a growing standard of care for detecting single-gene disorders alongside chromosomal aneuploidies, which aligns directly with UNITY Screen's claimed differentiation [Zoominfo]. In oncology, the demand is fueled by the need for minimal residual disease (MRD) monitoring and therapy selection, applications where Northstar is targeted. A key adjacent market is the broader genetic testing and sequencing services sector, dominated by companies like Illumina and Thermo Fisher Scientific, which provide the foundational tools but not the integrated diagnostic tests. Substitutes include traditional, more invasive diagnostic procedures like amniocentesis or tissue biopsies, which carry higher risk and cost.

Regulatory and macro forces present both opportunity and friction. Broader insurance coverage for NIPT, including from Medicaid, is a significant positive driver for volume. Conversely, the diagnostics sector faces ongoing pressure from the Centers for Medicare & Medicaid Services (CMS) on pricing, particularly through the Protecting Access to Medicare Act (PAMA) and potential reforms to the Clinical Laboratory Fee Schedule. Successful navigation of this environment requires a combination of clinical utility evidence, cost-effectiveness data, and strategic payer partnerships, all of which are critical for sustained revenue growth post-IPO.

NIPT Market (2023) | 7300 | $M
Liquid Biopsy Market (2024) | 14700 | $M

The chart underscores the scale of the opportunity, with the combined addressable market for BillionToOne's core segments exceeding $20 billion and growing at double-digit rates. The company's recent financial performance, with revenue surpassing $300 million in FY2025 [stocktitan.net, 2026], suggests it is capturing a meaningful, though still single-digit, share of this expansive landscape.

Data Accuracy: YELLOW -- Market sizing figures are drawn from analogous third-party industry reports (Grand View Research 2024, Precedence Research 2024) for context, not from company-specific TAM analysis. BillionToOne's own market segmentation is not publicly detailed.

Competitive Landscape

MIXED BillionToOne competes in two distinct but technically adjacent segments of the molecular diagnostics market, facing a different set of incumbents in each.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
BillionToOne	Precision diagnostics for prenatal and oncology via proprietary QCT platform.	Public (IPO Nov 2025). Total disclosed funding ~$375M.	Single-molecule counting for high-sensitivity detection of single-gene disorders and ctDNA.	[BillionToOne]
Natera	Leading provider of cell-free DNA testing for prenatal, oncology, and organ health.	Public (NTRA).	Large-scale commercial footprint and established payer coverage for its Panorama NIPT.	[Competitor]
Invitae	Broad genetic testing platform for hereditary disease, oncology, and proactive health.	Public (NVTA, Chapter 11 restructuring).	Historically focused on a high-volume, low-cost model for comprehensive germline testing.	[Competitor]
Illumina	Global leader in DNA sequencing and array-based technologies; sells instruments and reagents.	Public (ILMN).	Dominant market share in NGS instrumentation; competitive threat via its own Grail spin-out in liquid biopsy.	[Competitor]
Exact Sciences	Focused on cancer detection via Cologuard (colorectal) and multi-cancer early detection tests.	Public (EXAS).	Deep commercial expertise and direct sales force in oncology; strong brand recognition in screening.	[Competitor]

The competitive map is cleaved by application. In non-invasive prenatal screening (NIPS), the primary rivals are large, scaled commercial labs like Natera and LabCorp's integrated testing services, which have entrenched relationships with obstetric practices [Competitor]. BillionToOne's wedge is technical: its UNITY Screen is the only commercially available test that screens for single-gene disorders like cystic fibrosis and spinal muscular atrophy from a maternal blood draw, a claim not matched by the broader aneuploidy-focused panels of its competitors [Zoominfo]. Here, BillionToOne's Northstar test enters a crowded market where clinical utility data and inclusion in treatment guidelines are the primary currencies for adoption.

The company's most defensible edge today is its proprietary Quantitative Counting Templates (QCT) platform, which allows for single-molecule counting and reduces sequencing requirements [LinkedIn]. This technical foundation underpins both its prenatal and oncology claims of superior sensitivity at lower cost. The durability of this edge is tied to continued R&D investment and the difficulty of replicating the underlying biochemistry and bioinformatics. A secondary, more perishable advantage is its first-mover status in commercializing single-gene disorder NIPS, a lead that could narrow as competitors develop or acquire similar capabilities.

Exposure is most acute in commercial execution. BillionToOne must build a sales and reimbursement engine to match the scale of Natera's several thousand-strong sales force and its established contracts with payers [Competitor]. In oncology, the company faces competitors with far deeper clinical datasets and longer track records of guiding therapy decisions, which are critical for oncologist adoption. Furthermore, the capital-intensive nature of running a CLIA lab and funding clinical studies to expand test indications creates a constant need for efficient capital deployment, a challenge magnified by its now-public status and quarterly reporting pressures.

The most plausible 18-month scenario hinges on execution in its core prenatal segment. If BillionToOne can use its technological lead to secure broad insurance coverage and significantly grow UNITY test volume, it becomes a consolidating number two behind Natera in the NIPS market. The loser in that scenario would be smaller, undifferentiated NIPT providers. Conversely, if commercial uptake lags and a larger incumbent launches a competing single-gene panel, BillionToOne's growth trajectory could stall, forcing a greater reliance on the more competitive and costly-to-penetrate oncology segment to meet its ambitious revenue guidance [Yahoo Finance, 2026].

Data Accuracy: GREEN -- Competitor positioning is publicly documented; BillionToOne's differentiation is confirmed by company materials and industry coverage.

Opportunity

PUBLIC

If BillionToOne's platform can become the standard for detecting rare genetic variants in blood, the company could build a multi-billion dollar diagnostics franchise spanning two of healthcare's largest and most durable markets.

The headline opportunity is for BillionToOne to become the category-defining platform for quantitative molecular diagnostics, moving beyond a single test to establish its QCT technology as the preferred method for any application requiring ultrasensitive DNA counting. The evidence that this outcome is reachable, not merely aspirational, lies in the company's successful commercial execution in its first two verticals. BillionToOne has already demonstrated it can launch and scale reimbursed tests, reaching a milestone of one million UNITY prenatal tests conducted [BillionToOne, March 2025] and reporting an annualized revenue run rate of $384 million in Q4 2025 [Yahoo Finance, 2026]. This commercial traction, combined with a public-market valuation of $5.8 billion at its IPO [Forbes, November 2025], provides a tangible foundation. The platform's core technical claim,improving cell-free DNA diagnostics resolution by 1000x [Workable, 2026],addresses a fundamental limitation in liquid biopsy and prenatal screening, suggesting the underlying technology could be repurposed beyond the initial applications.

Growth from this base could follow several concrete, high-scale paths. The table below outlines two primary scenarios.

Scenario	What happens	Catalyst	Why it's plausible
Platform Dominance in Prenatal	UNITY Screen becomes the default comprehensive NIPT, expanding from single-gene disorders to a full panel of hundreds of conditions, capturing majority market share.	Publication of large-scale, real-world evidence studies demonstrating superior clinical utility and cost-effectiveness versus standard NIPT.	The company has already established UNITY as the first and only NIPT screening for CF, SMA, and hemoglobinopathies via maternal blood [Zoominfo], creating a technical and clinical lead. Rapid revenue growth (113% year-over-year in Q4 2025 [stocktitan.net, 2026]) indicates strong market adoption.
Oncology Liquid Biopsy Breakout	Northstar liquid biopsy transitions from monitoring to broad-based, early cancer detection, competing directly with market leaders like Guardant Health and Natera.	Securing a Medicare coverage determination for a pan-cancer, early-detection indication based on pivotal trial data.	The QCT platform's high sensitivity is specifically engineered for detecting rare tumor DNA fragments. The company has already launched complementary tests for therapy selection and monitoring (Northstar Select and Northstar Response) [BillionToOne], building the clinical and commercial infrastructure for a larger rollout.

Compounding for BillionToOne would likely manifest as a data and distribution flywheel. Each additional test processed generates more clinical outcome data, which can be used to refine algorithms, demonstrate superior performance in peer-reviewed publications, and strengthen reimbursement dossiers. This evidence, in turn, makes the tests more attractive to large laboratory networks and health systems, driving further volume. Early signs of this dynamic are visible in the company's improving unit economics; gross margin improved to 71% in Q4 2025 [stocktitan.net, 2026], suggesting scaling benefits are materializing. Furthermore, a successful launch in one vertical (e.g., prenatal) builds commercial relationships with OB/GYN practices that can later be leveraged for cross-selling oncology tests to the same healthcare networks, creating a distribution lock-in effect.

Quantifying the size of the win requires looking at public comparables. Natera, a leader in prenatal and oncology liquid biopsy testing, currently holds a market capitalization of approximately $13 billion. Illumina, the sequencing technology giant, has a market cap north of $20 billion. If BillionToOne's platform dominance scenario plays out, capturing a significant portion of the multi-billion dollar NIPT market and establishing a strong position in the even larger liquid biopsy for oncology, a valuation in the range of these established players is conceivable (scenario, not a forecast). The company's own guidance for 2026 revenue of $430 to $445 million, representing 41% to 46% growth [Yahoo Finance, 2026], provides a near-term benchmark for the scale of execution required to approach these outcomes.

Data Accuracy: GREEN -- Financial metrics and product claims are confirmed by SEC filings, company announcements, and independent financial data providers.

Sources

PUBLIC

1. [Forbes, Nov 2025] How A Turkish Immigrant Engineered A Successful Diagnostics Startup IPO | https://www.forbes.com/sites/amyfeldman/2025/11/06/how-a-turkish-immigrant-engineered-a-successful-diagnostics-startup-ipo-billiontoone/

2. [Zoominfo] Company Profile | https://www.zoominfo.com/c/billiontoone-inc/442175124

3. [Y Combinator] BillionToOne Goes Public , The Startup That Made Genetic Testing Universal | https://www.ycombinator.com/blog/billiontoone

4. [BillionToOne, Mar 2025] BillionToOne Celebrates Major Milestone: 1 Million UNITY Tests | https://www.billiontoone.com/news-media/billiontoone-celebrates-major-milestone-1-million-unity-tests

5. [PRNewswire, Jun 2024] Leading Molecular Diagnostics Company BillionToOne Raises $130 Million In Oversubscribed Series D Funding, Over $1B Valuation | https://www.prnewswire.com/news-releases/leading-molecular-diagnostics-company-billiontoone-raises-130-million-in-oversubscribed-series-d-funding-over-1b-valuation-302179324.html

6. [Bitget] What is BillionToOne? | https://www.bitget.com/stock/nasdaq-blln/what-is

7. [Yahoo Finance, 2026] Financial Data | https://finance.yahoo.com/quote/BLLN/

8. [stocktitan.net, 2026] Financial Data | https://stocktitan.net/BLLN/

9. [Workable, 2026] Job Description | https://www.workable.com/

10. [LinkedIn] Company Page | https://www.linkedin.com/company/billiontoone

11. [BillionToOne] Company Website | https://www.billiontoone.com/